Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

(Currently Amended) A pharmaceutical composition comprising a chemical compound of formula (I):

$$X_3$$
 X_4
 X_2
 X_1
 X_1
 X_2
 X_1
 X_2
 X_3
 X_4
 X_4
 X_1
 X_2
 X_3
 X_4
 X_4

wherein:

R₁ to R₃ are independently selected from hydrogen and lower alkyl;

X₁ is C-R_{4;}

X₂ is C-R₅;

X₃ is C-R₆;

X₄ is C-R₇;

R₄, R₅, R₆ and R₇ R₆ and R₇ are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkoyl, aryloyl, haloalkyl, haloalkoxy and alkylthio;[[,]] arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, alkylamino, dialkylamino, nitro, cyano, carboalkoxy, carboaryloxy and carboxy; and

Re is selected from hydrogen, halogen, alkyl, aryl, aryloxy, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, alkylamino, dialkylamino and cyano;

with the proviso that R4 to R7 are not all selected as hydrogen,

or a pharmaceutically acceptable salt, or addition compound thereof; in combination with a pharmaceutically acceptable carrier or excipient.

- 2. (Previously Presented) A pharmaceutical composition according to claim 1, wherein R₁ is selected from hydrogen and methyl.
- 3. (Previously Presented) A pharmaceutical composition according to claim 1, wherein R₂ is hydrogen.
- 4. (Previously Presented) A pharmaceutical composition according to claim 1, wherein R₃ is selected from hydrogen and methyl.
 - 5 8. (Cancelled)
- 9. (Previously Presented) A pharmaceutical composition according to claim 1, wherein two of R₄, R₅, R₆ and R₇ are hydrogen.
- 10. (Previously Presented) A pharmaceutical composition according to claim 9, wherein R₄ and R₆ are hydrogen.
- 11. (Previously Presented) A pharmaceutical composition according to claim 1, wherein two of R₄, R₅, R₆ and R₇ are independently selected from hydrogen, chlorine, fluorine, trifluoromethyl and bromine.
- 12. (Previously Presented) A pharmaceutical composition according to claim 1, wherein three of R₄, R₅, R₆ and R₇ are hydrogen.
- 13. (Previously Presented) A pharmaceutical composition according to claim 12, wherein R₄, R₆ and R₇ are hydrogen.
- 14. (Previously Presented) A pharmaceutical composition according to claim 1, wherein R₄ is hydrogen.
- 15. (Previously Presented) A pharmaceutical composition according to claim 1, wherein R₅ is halogen.
- 16. (Previously Presented) A pharmaceutical composition according to claim 1, wherein R₅ is hydrogen.
- 17. (Previously Presented) A pharmaceutical composition according to claim 1, wherein R₇ is halogen.

18. (Previously Presented) A pharmaceutical composition according to claim 1 which is selected from:

(RS) 7-chloro-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole,

(R5) 9-chloro-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole,

(RS) 7-chloro-8-methyl-I,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole,

(10aR) 7-chloro-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole,

(RS) 7-bromo-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole,

(3S, 10aR) 8-chloro-2-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole,

(10aR) 8-chloro-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole and

(3S, 10aR) 8-chloro-2-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole.

19 - 28. (Cancelled)

29. (Previously Presented) A method of treatment of obesity, comprising administering to a patient in need of such treatment an effective dose of a compound of formula (I) as set out in claim 1.

30 - 33. (Cancelled)

34. (Currently Amended) A process for the preparation of a compound of formula (I): according to claim 1,

$$X_3$$
 X_4
 X_2
 X_1
 X_2
 X_1
 X_2
 X_3
 X_4
 X_1
 X_2
 X_3
 X_4
 X_4
 X_2
 X_3
 X_4
 X_4
 X_4
 X_4
 X_4
 X_5
 X_7
 X_8
 X_8

wherein:

R₁ to R₃ are independently selected from hydrogen and lower alkyl;

X₁ is C-R₄;

X₂ is C-R₅;

X₃ is C-R₆;

X4 is C-R7;

R4, R5 and R7 are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkoyl, aryloyl, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, alkylamino, dialkylamino, nitro, cyano, carboalkoxy, carboaryloxy and carboxy; and

R₆ is selected from hydrogen, halogen, alkyl, aryl, aryloxy, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, alkylamino, dialkylamino and cyano;

with the proviso that R₄ to R₇ are not all selected as hydrogen, said process comprising the steps of:

(i) treating a compound of formula (IX) with an aldehyde of formula R, CHO and then exposing to acid to obtain a compound of formula (X), wherein X_1 , X_2 , X_3 , X_4 , R_2 and R_3 are as described in claim 1, and

$$X_3$$
 X_4
 X_2
 X_1
 X_2
 X_3
 X_4
 X_2
 X_1
 X_2
 X_1
 X_2
 X_1
 X_2
 X_1
 X_2
 X_3
 X_4
 X_3
 X_4
 X_2
 X_3
 X_4
 X_3
 X_4
 X_3
 X_4
 X_4
 X_3
 X_4
 X_4

- (ii) reduction of a compound of formula (X).
- 35. (New) A process according to claim 34 with the proviso that where R_1 to R_3 and three of R_4 to R_7 are selected from hydrogen, the remaining R_4 to R_7 is not selected from methoxy.
 - 36. (New) A process for the preparation of a compound of formula (I) said process comprising the steps of:
- (i) treating a compound of formula (IX) with an aldehyde of formula R, CHO and then exposing to acid to obtain a compound of formula (X), wherein X_1 , X_2 , X_3 , X_4 , R_2 and R_3 are as described in claim 1, and

(ii) reduction of a compound of formula (X).